Strategically Sensitive Area

The challenges of doing business across the spectrum of life sciences evolve globally in leaps and bounds. These are retention of market share, marketing arrangements, patent expiry, IP licensing, generics, unfair competition, strict safety and pricing regulations, product liability, privacy issues. The world’s pharmaceutical leaders spend billions of dollars on R&D, developing strong pharma brands, streamlining and commercializing the science of health.

Indeed, the complexity of this business and the regulatory environment make advising the life science sector no easy task. The rapidly changing Ukrainian regulatory field and anticipated attempts to pursue healthcare reform makes this niche advisory extremely unique and sophisticated.

The recent mess around the concept of reform, its stakeholders, as well as measures to eliminate corruption, displays the current interest around the situation in this strategic and, at the same time, very sensitive area. And after a hot spring in Parliament the UJBL attempts to shed light on life sciences in Ukraine.

Moreover, we look at the latest legislative novelties from the practical side, gathering expert opinions and critical points, bringing together arguments and experience into the contents of this concentrated June issue.

Happy reading,

Olga Usenko